Cargando…
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some patients, ICI efficacy remains reserved to a subgroup that is not yet fully characterized. Tissue based assays, such as Programm...
Autores principales: | Duchemann, Boris, Remon, Jordi, Naigeon, Marie, Mezquita, Laura, Ferrara, Roberto, Cassard, Lydie, Jouniaux, Jean Mehdi, Boselli, Lisa, Grivel, Jonathan, Auclin, Edouard, Desnoyer, Aude, Besse, Benjamin, Chaput, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761725/ https://www.ncbi.nlm.nih.gov/pubmed/33287347 http://dx.doi.org/10.3390/cancers12123625 |
Ejemplares similares
-
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
por: Duchemann, Boris, et al.
Publicado: (2021) -
CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022) -
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8(+) T cells in patients with advanced NSCLC
por: Naigeon, Marie, et al.
Publicado: (2023) -
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study
por: Carril-Ajuria, Lucia, et al.
Publicado: (2022) -
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
por: Coutzac, Clélia, et al.
Publicado: (2020)